Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY1225 Phase 2 Study in Obesity
NCT06254261Phase 2Recruiting
- Sponsor
- Raynovent Biotech
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of RAY1225 in obesity, sponsored by Raynovent Biotech. Started Feb 2024; status: recruiting.
02
Drugs
RAY1225
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06254261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254261.